Ranitidine hydrochloride injection ip?

Ranitidine hydrochloride injection IP refers to the injectable (parenteral) form of ranitidine that complies with the Indian Pharmacopoeia (IP). It is an H2 receptor antagonist used to reduce gastric acid secretion in conditions like ulcers, GERD, and for stress ulcer prophylaxis in hospitalized patients.

Key points:
- Common adult dose (IV or IM): 50 mg every 6–8 hours. Some regimens use 50 mg IV over 5–10 minutes or 25–50 mg IV bolus, depending on the protocol.
- Infusion option: 50 mg in 100 mL saline or compatible fluid infused slowly over several minutes.
- Pediatric dosing: weight-based and given under medical supervision.
- Renal impairment: dose adjustments may be needed; follow medical/clinical guidelines.
- Storage: typically room temperature, protect from light; discard if the solution is discolored or contains particulates.
- Precautions: monitor for hypersensitivity; adjust for renal disease; be aware of potential drug interactions (e.g., antacids can affect absorption of other drugs given orally).

Regulatory note:
- Since NDMA contamination concerns, ranitidine products have been withdrawn or recalled in many markets. Check your local regulatory authority (FDA, DCGI, etc.) and supplier for the current status and approved alternatives (famotidine, nizatidine, or proton pump inhibitors) before use.

If you want, tell me the exact edition/year of the IP you’re referring to or the specific information you need (e.g., monograph identity, assay specifics, impurities, etc.), and I can tailor the details.